relatlimab (BMS-986016) / BMS 
Welcome,         Profile    Billing    Logout  
 4 Diseases   51 Trials   51 Trials   979 News 


12345678910111213...1314»
  • ||||||||||  favezelimab (MK-4280) / Merck (MSD), relatlimab (BMS-986016) / BMS, fianlimab (REGN3767) / Regeneron
    Review, Journal:  Deciphering LAG-3: unveiling molecular mechanisms and clinical advancements. (Pubmed Central) -  Oct 19, 2024   
    Currently, with the approval of relatlimab, a LAG-3 blocking antibody, a third player, has been used in the fight against cancer...However, the complex biology of LAG-3 may hinder its full development as a therapeutic alternative. In this review, we provide in-depth insight into the biology of LAG-3 and its current and future development in cancer treatment.
  • ||||||||||  relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
    Review, Journal:  Advances in understanding the role of immune checkpoint LAG-3 in tumor immunity: a comprehensive review. (Pubmed Central) -  Sep 10, 2024   
    Despite the encouraging clinical potential of LAG-3, the physiological function and mechanism of action in tumors are still not well understood. In this review, we systematically summarized the structure of LAG-3, ligands of LAG-3, cell-specific functions and signaling of LAG-3, and the current status of LAG-3 inhibitors under development.
  • ||||||||||  Review, Journal, Adverse events, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker:  Updates and emerging trends in the management of immune-related adverse events associated with immune checkpoint inhibitor therapy. (Pubmed Central) -  Sep 5, 2024   
    Previously, we reviewed the mechanisms of immune-related adverse events (irAEs), strategies for management of irAEs, and highlighted similarities as well as differences amongst clinical guidelines from the National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO), Society for Immunotherapy of Cancer (SITC), and European Society for Medical Oncology (ESMO). Herein, we provide an update that includes discussion of changes to these clinical guidelines since our last review, the new LAG-3 targeted agents, emerging patterns of irAEs, and new directions for improved monitoring and treatment of irAEs that could incorporate interdisciplinary pharmacist-led teams, artificial intelligence, and pharmacogenomics.
  • ||||||||||  relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Trial completion date, Trial primary completion date:  CA209-6D9: Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases (clinicaltrials.gov) -  Aug 26, 2024   
    P1,  N=1, Active, not recruiting, 
    Herein, we provide an update that includes discussion of changes to these clinical guidelines since our last review, the new LAG-3 targeted agents, emerging patterns of irAEs, and new directions for improved monitoring and treatment of irAEs that could incorporate interdisciplinary pharmacist-led teams, artificial intelligence, and pharmacogenomics. Trial completion date: Dec 2026 --> Jun 2025 | Trial primary completion date: Dec 2025 --> Jun 2024
  • ||||||||||  A Case of Severe ICI-Colitis With Suprainfection (Exhibit Hall E) -  Aug 20, 2024 - Abstract #ACG2024ACG_2558;    
    Case Description/ An 81-year-old male with metastatic melanoma on nivolumab and relatlimab with biopsy-proven ICI colitis ( Figure 1A ) on prednisone initially presented to the hospital with diarrhea...He was then started on infliximab and ganciclovir with initial symptom improvement...GI pathogen panel confirmed C. diff infection, and the patient was started on fidaxomicin...Severe colitis (i.e., grade 3 or 4) may require steroid therapy in addition to infliximab or vedolizumab, usually dosed at 0, 2, and 6 weeks, and patients typically respond within a week...(A) Colonic mucosal inflammation and ulceration in immune checkpoint inhibitor-colitis. (B) Severe diffuse pseudomembranous colitis in setting of Clostridium difficile infection.
  • ||||||||||  relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
    Journal, PD(L)-1 Biomarker, IO biomarker:  LAG-3 and PD-1 synergize on CD8+ T (Pubmed Central) -  Aug 10, 2024   
    Enhanced efficacy has been demonstrated in melanoma patients with combined nivolumab (anti-PD-1) and relatlimab (anti-LAG-3) treatment, the first in its class to be FDA approved. LAG-3 and PD-1 combined to drive T
  • ||||||||||  relatlimab (BMS-986016) / BMS
    The Efficacy and Safety of Relatlimab/Nivolumab in Patients with Advanced Melanoma: A Systematic Review (Poster Area) -  Aug 5, 2024 - Abstract #EADV2024EADV_2704;    
    In conclusion, while relatlimab/nivolumab combination therapy has demonstrated promising results in terms of efficacy in melanoma patients, comparing it to existing treatments necessitates extensive research and longer follow-up periods. Further studies are essential to confirm its long-term effectiveness and safety.
  • ||||||||||  Journal, Adverse events, Checkpoint inhibition:  Adverse Events of PD-1, PD-L1, CTLA-4, and LAG-3 Immune Checkpoint Inhibitors: An Analysis of the FDA Adverse Events Database. (Pubmed Central) -  Jul 26, 2024   
    The LAG-3 inhibitor relatlimab reported fewer AEs, including pyrexia and pneumonia...This study provides a detailed overview of the 25 most common AEs associated with ICIs, offering valuable insights for clinical decision-making and AE management. Further research is necessary to elucidate the mechanisms underlying these AEs and to develop targeted interventions to enhance the safety and efficacy of ICI therapy in patients with cancer.
  • ||||||||||  relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Combination therapy, Metastases:  T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer (clinicaltrials.gov) -  Jul 22, 2024   
    P1/2,  N=5, Terminated, 
    Phase classification: P1/2 --> P1 | Completed --> Terminated; Business objectives have changed. N=18 --> 5 | Trial completion date: Dec 2023 --> Jul 2024 | Recruiting --> Terminated | Trial primary completion date: Dec 2022 --> Mar 2024; Slow recruitment
  • ||||||||||  relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Neoadjuvant nivolumab/relatlimab or nivolumab/ipilimumab in triple negative breast cancer with high tumor-infiltrating lymphocytes (TILs) (Barcelona Auditorium - Hall 2) -  Jul 16, 2024 - Abstract #ESMO2024ESMO_1653;    
    P2
    Most common adverse events included endocrinopathies: hypothyroidism (40.0% in nivo/ipi, 33.3% in nivo/rela), adrenal insufficiency (26.7% in nivo/ipi, 6.7% in nivo/rela) and diabetes (6.7% in nivo/rela). Conclusions We present the first exploratory clinical trial with short-term neoadjuvant immunotherapy without chemotherapy for patients with TNBC with high TILs and observed a pCR rate of 33% with nivo/ipi and 47% with nivo/rela, warranting further studies on efficacy and toxicity of chemotherapy-free immunotherapy for immunogenic TNBC.
  • ||||||||||  relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
    Trial completion date:  iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer (clinicaltrials.gov) -  Jun 13, 2024   
    P2,  N=25, Active, not recruiting, 
    This study establishes the feasibility and safety of dual targeting of PD-1 and LAG-3 before lung cancer surgery.ClinicalTrials.gov Indentifier: NCT04205552 . Trial completion date: Sep 2023 --> Sep 2024
  • ||||||||||  relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
    Biomarker, Trial primary completion date, Combination therapy, Metastases:  Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer (clinicaltrials.gov) -  May 3, 2024   
    P2,  N=59, Active, not recruiting, 
    Trial completion date: Feb 2024 --> Jun 2024 | Trial primary completion date: Feb 2024 --> Jun 2024 Trial primary completion date: May 2024 --> Feb 2024
  • ||||||||||  A phase 3 trial of fixed dose combinations of fianlimab (anti (Hall A; Poster Bd #: 389a) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_916;    
    P1, P3
    The primary endpoint is ORR and key secondary endpoints are PFS and overall survival. Additional secondary endpoints are duration of response, disease control rate, investigator-assessed ORR and PFS, safety, pharmacokinetics, and immunogenicity.
  • ||||||||||  A phase 2 trial of IO102-IO103 and nivolumab-relatlimab fixed-dose combination in previously untreated, unresectable melanoma. (Hall A; Poster Bd #: 386a) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_910;    
    P2, P3
    Secondary endpoints include safety assessed by Common Terminology Criteria for Adverse Events v 5.0 , progression-free survival (PFS) by RECIST v1.1, duration of disease response, and disease control rate. Exploratory correlative endpoints include assessment of changes in PD-L1 and IDO-expressing cells in the TME on paired tumor biopsies, identification of peripheral PD-L1 and IDO-reactive cells in the peripheral blood by ELISpot, and assessment of peripheral pre-treatment and on-treatment T cell clonality by TCR sequencing.